UroGen Pharma Analyst Ratings
UroGen Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/01/2023 | 149.31% | HC Wainwright & Co. | $23 → $54 | Maintains | Buy |
| 07/31/2023 | -16.9% | Goldman Sachs | $11 → $18 | Maintains | Neutral |
| 06/21/2023 | 6.19% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/15/2023 | 1.57% | Oppenheimer | → $22 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 6.19% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/02/2023 | 6.19% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 04/10/2023 | 6.19% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/16/2023 | 6.19% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/08/2023 | -53.83% | Jefferies | $35 → $10 | Downgrades | Buy → Hold |
| 12/12/2022 | 6.19% | HC Wainwright & Co. | $26 → $23 | Maintains | Buy |
| 04/27/2022 | -7.66% | Berenberg | → $20 | Initiates Coverage On | → Buy |
| 03/22/2022 | -49.22% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 01/18/2022 | 56.97% | HC Wainwright & Co. | $50 → $34 | Maintains | Buy |
| 04/27/2021 | 130.84% | HC Wainwright & Co. | $57 → $50 | Maintains | Buy |
| 04/17/2020 | 116.99% | Oppenheimer | $45 → $47 | Maintains | Outperform |
| 04/16/2020 | 163.16% | HC Wainwright & Co. | $53 → $57 | Reiterates | → Buy |
| 04/13/2020 | 144.69% | HC Wainwright & Co. | $75 → $53 | Maintains | Buy |
| 04/06/2020 | 107.76% | Oppenheimer | $47 → $45 | Maintains | Outperform |
| 01/13/2020 | 140.07% | Oppenheimer | $62 → $52 | Maintains | Outperform |
| 11/13/2019 | 80.06% | JP Morgan | $40 → $39 | Maintains | Neutral |
| 05/30/2019 | 89.29% | JP Morgan | → $41 | Initiates Coverage On | → Neutral |
| 05/29/2019 | 130.84% | Goldman Sachs | → $50 | Initiates Coverage On | → Neutral |
| 01/29/2019 | 278.58% | HC Wainwright & Co. | → $82 | Initiates Coverage On | → Buy |
| 11/08/2018 | 255.49% | Jefferies | → $77 | Assumes | → Buy |
| 09/14/2018 | 223.18% | Stifel | → $70 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/01/2023 | 149.31% | HC Wainwright公司 | $23→$54 | 维护 | 买 |
| 07/31/2023 | -16.9% | 高盛 | $11→$18 | 维护 | 中性 |
| 2023年6月21日 | 6.19% | HC Wainwright公司 | →$23 | 重申 | 购买→购买 |
| 2023年05月15日 | 1.57% | 奥本海默 | →$22 | 重申 | 跑赢→跑赢大盘 |
| 2023年05月15日 | 6.19% | HC Wainwright公司 | →$23 | 重申 | 购买→购买 |
| 05/02/2023 | 6.19% | HC Wainwright公司 | →$23 | 重申 | →购买 |
| 04/10/2023 | 6.19% | HC Wainwright公司 | →$23 | 重申 | →购买 |
| 02/16/2023 | 6.19% | HC Wainwright公司 | →$23 | 重申 | →购买 |
| 02/08/2023 | -53.83% | 杰富瑞 | $35→$10 | 评级下调 | 购买→Hold |
| 2022年12月12日 | 6.19% | HC Wainwright公司 | $26→$23 | 维护 | 买 |
| 04/27/2022 | -7.66% | 贝伦伯格 | →$20 | 开始承保 | →购买 |
| 03/22/2022 | -49.22% | 高盛 | $10→$11 | 维护 | 中性 |
| 01/18/2022 | 56.97% | HC Wainwright公司 | $50→$34 | 维护 | 买 |
| 04/27/2021 | 130.84% | HC Wainwright公司 | $57→$50 | 维护 | 买 |
| 04/17/2020 | 116.99% | 奥本海默 | $45→$47 | 维护 | 跑赢大盘 |
| 04/16/2020 | 163.16% | HC Wainwright公司 | $53→$57 | 重申 | →购买 |
| 04/13/2020 | 144.69% | HC Wainwright公司 | $75→$53 | 维护 | 买 |
| 04/06/2020 | 107.76% | 奥本海默 | $47→$45 | 维护 | 跑赢大盘 |
| 2020/01/13 | 140.07% | 奥本海默 | $62→$52 | 维护 | 跑赢大盘 |
| 2019年11月13日 | 80.06% | 摩根大通 | $40→$39 | 维护 | 中性 |
| 2019年05月30日 | 89.29% | 摩根大通 | →$41 | 开始承保 | →中性 |
| 2019年05月29日 | 130.84% | 高盛 | →$50 | 开始承保 | →中性 |
| 2019年01月29日 | 278.58% | HC Wainwright公司 | →$82 | 开始承保 | →购买 |
| 2018/08/11 | 255.49% | 杰富瑞 | →$77 | 假设 | →购买 |
| 2018年09月14日 | 223.18% | Stifel | →$70 | 开始承保 | →购买 |
What is the target price for UroGen Pharma (URGN)?
UroGen Pharma(URGN)的目标价是多少？
The latest price target for UroGen Pharma (NASDAQ: URGN) was reported by HC Wainwright & Co. on August 1, 2023. The analyst firm set a price target for $54.00 expecting URGN to rise to within 12 months (a possible 149.31% upside). 10 analyst firms have reported ratings in the last year.
优罗根制药(纳斯达克：URGN)的最新目标价是由HC Wainwright&Co.于2023年8月1日报道的。这家分析公司将目标价定为54美元，预计URGN将在12个月内上涨至(可能上涨149.31%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for UroGen Pharma (URGN)?
UroGen Pharma(URGN)的最新分析师评级是多少？
The latest analyst rating for UroGen Pharma (NASDAQ: URGN) was provided by HC Wainwright & Co., and UroGen Pharma maintained their buy rating.
优罗根制药(纳斯达克代码：URGN)的最新分析师评级由HC Wainwright&Co.提供，优罗根制药维持买入评级。
When is the next analyst rating going to be posted or updated for UroGen Pharma (URGN)?
UroGen Pharma(URGN)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与UroGen Pharma的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。UroGen Pharma的上一次评级是在2023年8月1日提交的，所以你应该预计下一次评级将在2024年8月1日左右的某个时候提供。
Is the Analyst Rating UroGen Pharma (URGN) correct?
分析师评级UroGen Pharma(URGN)正确吗？
While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a maintained with a price target of $23.00 to $54.00. The current price UroGen Pharma (URGN) is trading at is $21.66, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的UroGen Pharma(URGN)评级维持不变，目标价在23.00美元至54.00美元之间。UroGen Pharma(URGN)目前的交易价格为21.66美元，超出了分析师的预测区间。